Investigating the Accuracy of the openFDA API using the FDA Adverse Event Reporting System (FAERS)

被引:0
|
作者
Shin, Jennifer [1 ]
机构
[1] 8 Path Solut LLC, New York, NY 10024 USA
来源
2014 IEEE INTERNATIONAL CONFERENCE ON BIG DATA (BIG DATA) | 2014年
关键词
openFDA; FDA; adverse events; FDA Adverse Events Reporting System; FAERS; SURVEILLANCE;
D O I
暂无
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) is a database that contains information on adverse event and medication error reports submitted to the FDA. Each quarter the FDA releases the data to the public, but accessing the data requires researchers to download, import, and consolidate data for every quarter starting from 2004. In an effort to provide easier access to this, the FDA launched the openFDA initiative in June 2014, which gives the public API access to information about adverse events reports. Although the API enables easier access to the FAERS data, the quality of the API design and the features of the data set will determine the reliability of the information retrieved. Thus, errors in the API can result in inaccurate and unreliable data analysis. Furthermore, the number of adverse events reports retrieved by the API for a particular drug can differ from the FAERS data files due to the openFDA harmonization process and the existence of multiple entries and variations for any given drug name in the FAERS data files. Since there are no universal rule that can be used to identify errors or potential issues, we propose evaluating the openFDA API by searching for a particular drug (brand name), Yaz, and the generic name, Drospirenone Ethinyl Estradiol, and comparing the results against the FAERS data files. Our results show that in the case of Yaz, the openFDA API and the drug harmonization process is inaccurate and inconsistent.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database
    Morris, Robert
    Ali, Rahinatu
    Cheng, Feng
    CURRENT DRUG TARGETS, 2024, 25 (07) : 454 - 464
  • [2] Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
    He, Chang-Zhu
    Qiu, Qin
    Lu, Song-Jie
    Xue, Fu-Li
    Liu, Jun-Qiao
    He, Yu
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [3] A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS)
    Zou, Wenbin
    Yang, Han
    Xi, Yu
    Zeng, Chenxi
    Chen, Wei
    Fu, Xiangning
    HELIYON, 2024, 10 (17)
  • [4] Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
    Wen, Ming-Tao
    Li, Jia-Cheng
    Lu, Bo-Wen
    Shao, Hua-Rong
    Ling, Pei-Xue
    Liu, Fei
    Li, Gang
    Luo, Di
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [5] Pharmacovigilance Analysis Of FDA Adverse Event Reporting System (FAERS) Events For Inclisiran
    Rajak, Kripa
    Halder, Anupam
    Gautam, Seema Sharma
    Khanal, Resha
    Atrash, Anas
    Goswami, Rohan
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43
  • [6] A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
    Pan, Yunyan
    Wang, Yu
    Zheng, Yifan
    Chen, Jie
    Li, Jia
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [7] Combined nephrotoxicity of Polymyxins and Vancomycin: a study on adverse event reporting for monotherapy versus combinations using the FDA adverse event reporting system (FAERS)
    Zhan, Ruijia
    Lin, Jiageng
    Dai, Miao
    Ji, Bo
    He, Xianxia
    Jiang, Zhihui
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [8] Atezolizumab and severe cutaneous adverse reactions: a disproportionality analysis using FDA Adverse Event Reporting System (FAERS)
    Pecere, Alessandro
    Bisinella, Giulia Carlotta
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (SUPPL 1) : 35 - 35
  • [9] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    BMC Pharmacology and Toxicology, 24
  • [10] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (11) : 1447 - 1452